Amneal Pharmaceuticals Inc (NYSE:AMRX) has earned a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.23.
Several brokerages recently commented on AMRX. Raymond James lifted their price target on shares of S&P Global from $226.00 to $246.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th. Piper Jaffray Companies set a $92.00 price target on shares of Wintrust Financial and gave the stock a “buy” rating in a research note on Monday, July 8th. Barclays set a $5.00 price target on shares of Amneal Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Finally, ValuEngine lowered shares of Whiting USA Trust II from a “hold” rating to a “sell” rating in a research note on Tuesday, May 7th.
Shares of AMRX traded down $0.19 during midday trading on Monday, reaching $3.51. The stock had a trading volume of 4,808,697 shares, compared to its average volume of 1,193,479. Amneal Pharmaceuticals has a 1-year low of $3.41 and a 1-year high of $24.48. The business has a fifty day moving average price of $7.12. The firm has a market capitalization of $1.11 billion, a P/E ratio of 3.69, a price-to-earnings-growth ratio of 0.28 and a beta of 1.51. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The firm had revenue of $446.00 million during the quarter, compared to analyst estimates of $438.18 million. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Research analysts expect that Amneal Pharmaceuticals will post 0.74 earnings per share for the current year.
In other Amneal Pharmaceuticals news, SVP Joseph Todisco acquired 15,000 shares of the stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $9.88 per share, with a total value of $148,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Andrew S. Boyer acquired 19,000 shares of the stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $9.46 per share, for a total transaction of $179,740.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 41,000 shares of company stock worth $387,300 over the last three months. 26.34% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 2.1% in the fourth quarter. BlackRock Inc. now owns 6,053,727 shares of the company’s stock valued at $81,909,000 after acquiring an additional 121,800 shares in the last quarter. TCW Group Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 2.8% in the first quarter. TCW Group Inc. now owns 2,302,363 shares of the company’s stock valued at $32,625,000 after acquiring an additional 63,423 shares in the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Amneal Pharmaceuticals by 1.7% in the first quarter. Neuberger Berman Group LLC now owns 1,709,999 shares of the company’s stock valued at $24,227,000 after acquiring an additional 28,747 shares in the last quarter. Norges Bank purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $18,243,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Amneal Pharmaceuticals by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 889,980 shares of the company’s stock valued at $12,041,000 after acquiring an additional 108,455 shares in the last quarter. 36.05% of the stock is currently owned by institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Story: How is net asset value different from market price?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.